Bavarian Nordic's 2021 will be full of development

Bavarian Nordic's fiscal report does not hold any surprises, since most important figures have already been presented. However, the firm's year will be busy and full of expenses, especially due to one particular vaccine program.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

The fiscal report from biotechnology company Bavarian Nordic has little news to share, since the majority of the relevant figures have already been published.

In January, the firm sought to accommodate its shareholders by making its preliminary financial report public early on, and this week, the firm's guidance for 2021 was presented in connection with its large-scale capital raising round.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs